FDA Inspection 1256688 — Zhejiang Raybow Pharmaceutical Co., Ltd.
The FDA completed an inspection of Zhejiang Raybow Pharmaceutical Co., Ltd. on November 1, 2024 in Taizhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 1, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)